Lung cancer

a. Identifying how lung cancers (NSCLC/SCLC/Mesothelioma) adapt and evolve through treatment and over time: ideally focus on tumour material where primary and matched paired metastatic biopsies and germline DNA are available with in depth clinical annotation.
b. Identifying the origins of the lethal subclone and how does therapy affect the subclonal composition of the relapsed tumour
c. Identification of drivers of cancer progression, diversification and adaptation/drug resistance; identification of combinatorial driver events that canalise tumours through distinct histological trajectories.

a. Address the preponderance of distinct molecular cohorts of lung cancers within individual patient groups e.g. why are female non-smokers particularly susceptible to the acquisition of EGFR activating mutations or ALK rearrangements?
b. Address the transformation of particular NSCLC entities- eg NSCLC to Small cell transformation and the genomic drivers of adenosquamous carcinoma
c. Decipher therapeutically tractable events in malignant mesothelioma

a. Address how the immune microenvironment edits and constrains tumour evolution?
b. Identify and validate new genomic markers predictive of benefit from immunotherapy

a. Through warm autopsy programs the GeCIP will address how well circulating free tumour DNA and the CTC fraction reflects tumour diversity in the primary and metastatic tumour.
b. Generate new approaches to single cell genomics and early diagnosis

a. Through warm autopsy programs the GeCIP will address how well circulating free tumour DNA and the CTC fraction reflects tumour diversity in the primary and metastatic tumour.
b. Generate new approaches to single cell genomics and early diagnosis